PEPtalk Mon, 12 Oct 2026 06:00:01 -0400 https://www.buzzsprout.com/2654451 en-us © 2026 PEPtalk yes 97276afe-e083-5b56-bc9d-9d28abd1f483 Jake & Cynthia episodic false A twice-weekly, AI-hosted podcast on the peptide market. Mondays: deep dives — a fast pulse on the big GLP-1 names plus one molecule unpacked in full. Fridays: the week in review — the biggest stories from the lab, the market, and the regulators, all in about fifteen minutes. Hosted by Jake and Cynthia. For research and informational purposes only — not medical advice.


]]> Buzzsprout (https://www.buzzsprout.com) Jake & Cynthia https://storage.buzzsprout.com/k2lw1zakl51jl0wbh110zycy8pah?.jpg PEPtalk https://www.buzzsprout.com/2654451 5: Peptalk Deep Dive — Tesamorelin 5: Peptalk Deep Dive — Tesamorelin Last week: Sermorelin, the elegant idea. This week: Tesamorelin - its bigger sibling, and the evidence heavyweight of the growth hormone peptide world. 

Jake and Cynthia unpack Tesamorelin — the full forty-four amino acid growth hormone releasing factor with a protective chemical cap, two Phase three trials, visceral fat down fourteen to eighteen percent, lean body mass up, liver fat down, and an FDA approval (Egrifta) with a formulation modernization: Egrifta WR, approved March 2025 and in pharmacies since September 2025. 

Plus the honest limits: a narrow approved use, maintenance required, and long-term cardiovascular safety still an open file. 

Also: the weekly GLP pulse — the growing evidence that GLP-1s curb drug and alcohol cravings (PBS NewsHour), plus new research on compulsive gambling and shopping (CBS News).

For research and informational purposes only — not medical advice.

Sources:

•  PBS NewsHour — The evidence suggesting GLP-1s can curb drug and alcohol cravings (Oct 7, 2026): https://www.pbs.org/newshour/show/the-evidence-suggesting-glp-1s-can-curb-drug-and-alcohol-cravings

•  CBS News — Doctor explains how GLP-1 drugs could help reduce gambling, shopping addiction (Oct 9, 2026): https://www.cbsnews.com/news/glp-1-drugs-wharton-study-impulsive-spending/

•  Medscape — Tesamorelin reduces visceral fat in HIV-associated lipodystrophy (Phase 3 data): https://www.medscape.com/viewarticle/732450

•  Theratechnologies / Drugs.com — FDA Approval for EGRIFTA WR (tesamorelin F8), March 25, 2025: https://www.drugs.com/newdrugs/theratechnologies-receives-fda-approval-egrifta-wr-tesamorelin-f8-excess-visceral-abdominal-fat-6482.html

•  Theratechnologies — Availability of EGRIFTA WR, September 5, 2025: https://www.cbj.ca/theratechnologies-announces-availability-of-egrifta-wr-tesamorelin-for-injection-to-reduce-excess-abdominal-fat-in-adults-with-hiv-and-lipodystrophy/

•  Stanley & Grinspoon — Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV-Infected Patients With Abdominal Fat Accumulation (JAMA / PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC4363137/

•  Peptpedia — Tesamorelin (Egrifta): FDA-Approved, Visceral Fat Data: https://peptpedia.org/peptide/tesamorelin

]]> Last week: Sermorelin, the elegant idea. This week: Tesamorelin - its bigger sibling, and the evidence heavyweight of the growth hormone peptide world. 

Jake and Cynthia unpack Tesamorelin — the full forty-four amino acid growth hormone releasing factor with a protective chemical cap, two Phase three trials, visceral fat down fourteen to eighteen percent, lean body mass up, liver fat down, and an FDA approval (Egrifta) with a formulation modernization: Egrifta WR, approved March 2025 and in pharmacies since September 2025. 

Plus the honest limits: a narrow approved use, maintenance required, and long-term cardiovascular safety still an open file. 

Also: the weekly GLP pulse — the growing evidence that GLP-1s curb drug and alcohol cravings (PBS NewsHour), plus new research on compulsive gambling and shopping (CBS News).

For research and informational purposes only — not medical advice.

Sources:

•  PBS NewsHour — The evidence suggesting GLP-1s can curb drug and alcohol cravings (Oct 7, 2026): https://www.pbs.org/newshour/show/the-evidence-suggesting-glp-1s-can-curb-drug-and-alcohol-cravings

•  CBS News — Doctor explains how GLP-1 drugs could help reduce gambling, shopping addiction (Oct 9, 2026): https://www.cbsnews.com/news/glp-1-drugs-wharton-study-impulsive-spending/

•  Medscape — Tesamorelin reduces visceral fat in HIV-associated lipodystrophy (Phase 3 data): https://www.medscape.com/viewarticle/732450

•  Theratechnologies / Drugs.com — FDA Approval for EGRIFTA WR (tesamorelin F8), March 25, 2025: https://www.drugs.com/newdrugs/theratechnologies-receives-fda-approval-egrifta-wr-tesamorelin-f8-excess-visceral-abdominal-fat-6482.html

•  Theratechnologies — Availability of EGRIFTA WR, September 5, 2025: https://www.cbj.ca/theratechnologies-announces-availability-of-egrifta-wr-tesamorelin-for-injection-to-reduce-excess-abdominal-fat-in-adults-with-hiv-and-lipodystrophy/

•  Stanley & Grinspoon — Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV-Infected Patients With Abdominal Fat Accumulation (JAMA / PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC4363137/

•  Peptpedia — Tesamorelin (Egrifta): FDA-Approved, Visceral Fat Data: https://peptpedia.org/peptide/tesamorelin

]]> Buzzsprout-19941709 Mon, 12 Oct 2026 06:00:00 -0400 640 1 5 full false 4: Peptalk Week in Review — October 9, 2026 4: Peptalk Week in Review — October 9, 2026 This week: both Lilly and Novo converged on $499/month cash pricing — and we walk the whole price ladder from list price to TrumpRx to the gray market. 

Plus: Petrelintide's Phase 2 amylin data (up to 10.7% at 42 weeks with placebo-like tolerability) and its diabetes sister trial, retatrutide's low-dose readout (12.7% at just 4 mg), Trevogrumab's muscle-preservation data (70% of MRI-measured muscle loss prevented), Survodutide's Phase 3 diabetes trial (up to 13.1%), 


CagriSema's data blitz ahead of an expected October FDA decision, the WHO's first childhood-obesity guidelines vs. strong teen GLP-1 data, Orforglipron's heart-safety clearance, a compounded-glutathione recall, and two-year data on J&J's oral peptide for psoriasis.

For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.

**Sources:**


- The Educated Patient — Lilly + Novo reduce GLP-1 costs in the post-shortage era ($499 cash pricing): https://www.theeducatedpatient.com/view/eli-lilly-novo-nordisk-reduce-glp-1-costs-in-post-shortage-era


- Pharmaphorum — Novo Nordisk cuts GLP-1 prices for cash buyers (NovoCare): https://pharmaphorum.com/news/novo-nordisk-cuts-glp-1-prices-cash-buyers

- Retail TouchPoints — TrumpRx.gov lower-price promise (MFN pricing, GoodRx integration): https://www.retailtouchpoints.com/features/news-briefs/trumprx-gov-promises-lower-prices-on-popular-prescription-drugs


- White House fact sheet — GLP-1 Bridge Medicare program ($50 copay, 600,000 seniors): https://www.whitehouse.gov/fact-sheets/2026/09/fact-sheet-president-donald-j-trump-announces-lower-drug-prices-for-all-50-state-medicaid-programs/


- Biocare Nutrition — GLP-1 cost without insurance: https://biocarenutrition.com/blogs/biocare-blog/glp-1-cost-without-insurance.


- Dispense Times — the GLP-1 showdown: TrumpRx, compounding crackdowns, and the new era of drug pricing: https://dispensetimes.com/the-glp-1-showdown-trumprx-compounding-crackdowns-and-the-new-era-of-drug-pricing/


- Zealand Pharma announcement — petrelintide ZUPREME-1 Phase 2 data, The Lancet Diabetes & Endocrinology publication, EASD 2026 presentation: https://business.theeveningleader.com/theeveningleader/article/gnwcq-2026-9-29-zealand-pharma-to-present-additional-data-from-phase-2-zupreme-1-trial-for-petrelintide-at-easd-2026-and-announces-publication-of-trial-results-in-the-lancet-diabetes-and-endocrinology


- Reuters (Oct 7, 2026) — petrelintide ZUPREME-2 in type 2 diabetes (up to 9.2% at 28 weeks): https://www.reuters.com/business/healthcare-pharmaceuticals/zealand-roches-obesity-drug-helps-patients-lose-up-92-weight-mid-stage-trial-2026-10-07/


- Eli Lilly press release (Jul 23, 2026) — retatrutide Phase 3 (29.8 lb / 12.7% at 4 mg; FDA filing Q1 2027): https://lilly.mediaroom.com/2026-07-23-Lillys-triple-agonist,-retatrutide,-successful-in-two-additional-Phase-3-obesity-trials,-delivering-significant-improvements-in-weight-and-A1C?asPDF=1


- Regeneron press release (Oct 1, 2026) — COURAGE Phase 2 trevogrumab muscle-loss prevention (70% MRI substudy): https://www.globenewswire.com/news-release/2026/10/01/3373155/0/en/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass-and-muscle-loss-during-glp-1-receptor-agonist-induced-weight-loss.html


- Zealand Pharma press release (Oct 1, 2026) — survodutide SYNCHRONIZE-2 Phase 3 (up to 13.1% at 76 weeks, NEJM): https://www.globenewswire.com/news-release/2026/10/01/3372565/0/en/zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-.html


- TradingView weekly recap — HRS-1596 licensing and CagriSema 52-week EASD results: https://www.tradingview.com/news/tradingview:67ef0d4ddfa76:0-weekly-recap-hrs-1596-licensing-deal-and-cagrisema-52-week-trial-results/


- WHO — launch of guidelines on integrated management of obesity in children and adolescents (Oct 7, 2026): https://www.who.int/news-room/events/detail/2026/10/07/default-calendar/launch-of-who-guidelines--integrated-management-of-obesity-in-children-and-adolescents


- Reuters (Oct 7, 2026) — WHO endorses lifestyle changes over GLP-1 drugs in child-obesity fight: https://www.reuters.com/business/healthcare-pharmaceuticals/who-endorses-lifestyle-changes-over-glp-1-drugs-child-obesity-fight-2026-10-07/


- Seoul Economic Daily (Oct 6, 2026) — ecnoglutide Phase 1b in obese adolescents (up to 12.1% at 20 weeks): https://en.sedaily.com/technology/2026/10/06/hk-innons-glp-1-obesity-drug-cuts-teen-weight-up-to-121


- Pharmacy Times (Oct 1, 2026) — orforglipron ACHIEVE-4 CV safety vs. insulin glargine: https://www.pharmacytimes.com/view/orforglipron-shows-cv-safety-vs-insulin-glargine-in-achieve-4


- USA Today (Oct 2, 2026) — Greenwich Rx compounded-glutathione recall: https://www.usatoday.com/story/money/consumer-protection/recalls-alerts/2026/10/02/injectables-drugs-recalled-greenwich-rx/92055116007/


- Johnson & Johnson press release (Oct 2, 2026) — ICOTYDE (icotrokinra) 2-year ICONIC-TOTAL data, EADV 2026: https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-icotyde-icotrokinra-data-in-difficult-to-treat-plaque-psoriasis-with-proven-durability-through-2-years-affirming-its-use-as-a-powerful-first-line-systemic-therapy

]]> This week: both Lilly and Novo converged on $499/month cash pricing — and we walk the whole price ladder from list price to TrumpRx to the gray market. 

Plus: Petrelintide's Phase 2 amylin data (up to 10.7% at 42 weeks with placebo-like tolerability) and its diabetes sister trial, retatrutide's low-dose readout (12.7% at just 4 mg), Trevogrumab's muscle-preservation data (70% of MRI-measured muscle loss prevented), Survodutide's Phase 3 diabetes trial (up to 13.1%), 


CagriSema's data blitz ahead of an expected October FDA decision, the WHO's first childhood-obesity guidelines vs. strong teen GLP-1 data, Orforglipron's heart-safety clearance, a compounded-glutathione recall, and two-year data on J&J's oral peptide for psoriasis.

For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.

**Sources:**


- The Educated Patient — Lilly + Novo reduce GLP-1 costs in the post-shortage era ($499 cash pricing): https://www.theeducatedpatient.com/view/eli-lilly-novo-nordisk-reduce-glp-1-costs-in-post-shortage-era


- Pharmaphorum — Novo Nordisk cuts GLP-1 prices for cash buyers (NovoCare): https://pharmaphorum.com/news/novo-nordisk-cuts-glp-1-prices-cash-buyers

- Retail TouchPoints — TrumpRx.gov lower-price promise (MFN pricing, GoodRx integration): https://www.retailtouchpoints.com/features/news-briefs/trumprx-gov-promises-lower-prices-on-popular-prescription-drugs


- White House fact sheet — GLP-1 Bridge Medicare program ($50 copay, 600,000 seniors): https://www.whitehouse.gov/fact-sheets/2026/09/fact-sheet-president-donald-j-trump-announces-lower-drug-prices-for-all-50-state-medicaid-programs/


- Biocare Nutrition — GLP-1 cost without insurance: https://biocarenutrition.com/blogs/biocare-blog/glp-1-cost-without-insurance.


- Dispense Times — the GLP-1 showdown: TrumpRx, compounding crackdowns, and the new era of drug pricing: https://dispensetimes.com/the-glp-1-showdown-trumprx-compounding-crackdowns-and-the-new-era-of-drug-pricing/


- Zealand Pharma announcement — petrelintide ZUPREME-1 Phase 2 data, The Lancet Diabetes & Endocrinology publication, EASD 2026 presentation: https://business.theeveningleader.com/theeveningleader/article/gnwcq-2026-9-29-zealand-pharma-to-present-additional-data-from-phase-2-zupreme-1-trial-for-petrelintide-at-easd-2026-and-announces-publication-of-trial-results-in-the-lancet-diabetes-and-endocrinology


- Reuters (Oct 7, 2026) — petrelintide ZUPREME-2 in type 2 diabetes (up to 9.2% at 28 weeks): https://www.reuters.com/business/healthcare-pharmaceuticals/zealand-roches-obesity-drug-helps-patients-lose-up-92-weight-mid-stage-trial-2026-10-07/


- Eli Lilly press release (Jul 23, 2026) — retatrutide Phase 3 (29.8 lb / 12.7% at 4 mg; FDA filing Q1 2027): https://lilly.mediaroom.com/2026-07-23-Lillys-triple-agonist,-retatrutide,-successful-in-two-additional-Phase-3-obesity-trials,-delivering-significant-improvements-in-weight-and-A1C?asPDF=1


- Regeneron press release (Oct 1, 2026) — COURAGE Phase 2 trevogrumab muscle-loss prevention (70% MRI substudy): https://www.globenewswire.com/news-release/2026/10/01/3373155/0/en/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass-and-muscle-loss-during-glp-1-receptor-agonist-induced-weight-loss.html


- Zealand Pharma press release (Oct 1, 2026) — survodutide SYNCHRONIZE-2 Phase 3 (up to 13.1% at 76 weeks, NEJM): https://www.globenewswire.com/news-release/2026/10/01/3372565/0/en/zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-.html


- TradingView weekly recap — HRS-1596 licensing and CagriSema 52-week EASD results: https://www.tradingview.com/news/tradingview:67ef0d4ddfa76:0-weekly-recap-hrs-1596-licensing-deal-and-cagrisema-52-week-trial-results/


- WHO — launch of guidelines on integrated management of obesity in children and adolescents (Oct 7, 2026): https://www.who.int/news-room/events/detail/2026/10/07/default-calendar/launch-of-who-guidelines--integrated-management-of-obesity-in-children-and-adolescents


- Reuters (Oct 7, 2026) — WHO endorses lifestyle changes over GLP-1 drugs in child-obesity fight: https://www.reuters.com/business/healthcare-pharmaceuticals/who-endorses-lifestyle-changes-over-glp-1-drugs-child-obesity-fight-2026-10-07/


- Seoul Economic Daily (Oct 6, 2026) — ecnoglutide Phase 1b in obese adolescents (up to 12.1% at 20 weeks): https://en.sedaily.com/technology/2026/10/06/hk-innons-glp-1-obesity-drug-cuts-teen-weight-up-to-121


- Pharmacy Times (Oct 1, 2026) — orforglipron ACHIEVE-4 CV safety vs. insulin glargine: https://www.pharmacytimes.com/view/orforglipron-shows-cv-safety-vs-insulin-glargine-in-achieve-4


- USA Today (Oct 2, 2026) — Greenwich Rx compounded-glutathione recall: https://www.usatoday.com/story/money/consumer-protection/recalls-alerts/2026/10/02/injectables-drugs-recalled-greenwich-rx/92055116007/


- Johnson & Johnson press release (Oct 2, 2026) — ICOTYDE (icotrokinra) 2-year ICONIC-TOTAL data, EADV 2026: https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-icotyde-icotrokinra-data-in-difficult-to-treat-plaque-psoriasis-with-proven-durability-through-2-years-affirming-its-use-as-a-powerful-first-line-systemic-therapy

]]> Jake & Cynthia Buzzsprout-19934599 Fri, 09 Oct 2026 06:00:00 -0400 714 1 4 full false 3: Peptalk Deep Dive — Sermorelin 3: Peptalk Deep Dive — Sermorelin Sermorelin is having a moment. 

Jake and Cynthia unpack the growth hormone peptide everyone's pivoting to: what it is (a copy of your body's own GHRH signal), how it works (pulsatile, feedback-intact), what the research actually shows (nocturnal GH up, lean mass up in men, skin thickness up in both sexes), and why it's trending now that ipamorelin is restricted. Plus its surprising pedigree: an FDA-approved drug (Geref, 1997) that left the market for business reasons, not safety. Honest bottom line included. 

Also: the weekly GLP pulse — Retatrutide goes mainstream, CagriSema food-noise data, and a $2.6B oral GLP-1 deal.

For research and informational purposes only — not medical advice.

Sources:

•  Prime Lab Peptides — sermorelin pituitary signaling (Khorram 1997): https://primelabpeptides.com/blogs/news/how-does-sermorelin-influence-pituitary-signaling-pathways-in-endocrine-research

•  Sermorelin myths vs. reality (Geref 1997/2008, 503A compounding): https://medium.com/@esochabiakasikhi/sermorelin-peptide-myths-vs-reality-bdeea758b588

•  Scientific American — growth hormone peptides and the evidence: https://www.scientificamerican.com/article/growth-hormone-peptides-promise-to-stall-aging-but-does-the-science-stack-up/

•  The BMJ — retatrutide TRIUMPH Phase 3: http://www.bmj.com/content/395/bmj-2026-101016

•  Pharmacy Times — CagriSema curbs food noise: https://www.pharmacytimes.com/view/cagrisema-curbs-food-noise-organ-fat-in-patients-with-obesity-t2d-respectively

•  Business News Today — Novo–Hengrui $2.6B deal: https://business-news-today.com/hengrui-lands-2-6bn-novo-nordisk-deal-for-experimental-weekly-oral-obesity-drug/

]]> Sermorelin is having a moment. 

Jake and Cynthia unpack the growth hormone peptide everyone's pivoting to: what it is (a copy of your body's own GHRH signal), how it works (pulsatile, feedback-intact), what the research actually shows (nocturnal GH up, lean mass up in men, skin thickness up in both sexes), and why it's trending now that ipamorelin is restricted. Plus its surprising pedigree: an FDA-approved drug (Geref, 1997) that left the market for business reasons, not safety. Honest bottom line included. 

Also: the weekly GLP pulse — Retatrutide goes mainstream, CagriSema food-noise data, and a $2.6B oral GLP-1 deal.

For research and informational purposes only — not medical advice.

Sources:

•  Prime Lab Peptides — sermorelin pituitary signaling (Khorram 1997): https://primelabpeptides.com/blogs/news/how-does-sermorelin-influence-pituitary-signaling-pathways-in-endocrine-research

•  Sermorelin myths vs. reality (Geref 1997/2008, 503A compounding): https://medium.com/@esochabiakasikhi/sermorelin-peptide-myths-vs-reality-bdeea758b588

•  Scientific American — growth hormone peptides and the evidence: https://www.scientificamerican.com/article/growth-hormone-peptides-promise-to-stall-aging-but-does-the-science-stack-up/

•  The BMJ — retatrutide TRIUMPH Phase 3: http://www.bmj.com/content/395/bmj-2026-101016

•  Pharmacy Times — CagriSema curbs food noise: https://www.pharmacytimes.com/view/cagrisema-curbs-food-noise-organ-fat-in-patients-with-obesity-t2d-respectively

•  Business News Today — Novo–Hengrui $2.6B deal: https://business-news-today.com/hengrui-lands-2-6bn-novo-nordisk-deal-for-experimental-weekly-oral-obesity-drug/

]]> Jake & Cynthia Buzzsprout-19908478 Mon, 05 Oct 2026 06:00:00 -0400 604 1 3 full false 2: Peptalk Week in Review — October 2, 2026 2: Peptalk Week in Review — October 2, 2026 EASD 2026 in Milan turned into a Lilly showcase — and Jake and Cynthia round up the whole week.

Stories this week: 

(1) Retatrutide's full Phase 3 TRIUMPH-1 data — up to 25% weight loss at 80 weeks, plus knee osteoarthritis and sleep apnea improvements — and TRIUMPH-2 in type 2 diabetes published in The Lancet; Lilly expects to file with the FDA by end of March 2027. 

(2) Lilly's amylin + tirzepatide combo EloraTZP: 23.3% at 48 weeks heading to Phase 3, with a real tolerability question — plus the wider amylin stacking moment. 

(3) Boehringer/Zealand's survodutide Phase 3 SYNCHRONIZE-2: 13.1% at 76 weeks, published in NEJM the same day. 

(4) Novo's oral strategy: up to $2.6B for ex-China rights to Hengrui's weekly oral GLP-1/GIP, real-world data on switching to the Wegovy pill, and Wegovy liver-fat normalization. 

(5) The FDA's warning letter to Empower Pharmacy over mass-produced compounded GLP-1s — its fourth. Plus a market check: LLY dipped on great news, NVO down ~24% YTD.

For research and informational purposes only — not medical advice.

**Sources:**
- Cardiac Wire — TRIUMPH-1 full Phase 3: https://cardiacwire.com/a-new-king-of-the-glp-1s-could-be-crowned/
- USA Today — TRIUMPH-2 / Lilly FDA filing plans: https://www.usatoday.com/story/money/personal-finance/healthcare/2026/09/30/retatrutide-glp-1-eli-lilly-weight-loss/92019663007/
- BioSpace — EloraTZP Phase 2b: https://www.biospace.com/drug-development/superior-weight-loss-blood-sugar-control-propel-lillys-amylin-gip-glp-1-combo-into-phase-3
- Zealand Pharma — SYNCHRONIZE-2: https://mfn.se/one/a/zealand-pharma/zealand-pharma-announces-boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-diabetes-a9e0d011
- Business News Today — Novo–Hengrui $2.6B deal: https://business-news-today.com/hengrui-lands-2-6bn-novo-nordisk-deal-for-experimental-weekly-oral-obesity-drug/
- Reuters — OCTANE real-world switching study: https://www.reuters.com/legal/litigation/patients-switching-to-novo-nordisks-wegovy-pill-shots-lose-more-weight-real-2026-09-30/
- Becker's Hospital Review — FDA warning letter to Empower Pharmacy: https://www.beckershospitalreview.com/pharmacy/fda-flags-sterility-concerns-at-major-glp-1-compounder/

]]> EASD 2026 in Milan turned into a Lilly showcase — and Jake and Cynthia round up the whole week.

Stories this week: 

(1) Retatrutide's full Phase 3 TRIUMPH-1 data — up to 25% weight loss at 80 weeks, plus knee osteoarthritis and sleep apnea improvements — and TRIUMPH-2 in type 2 diabetes published in The Lancet; Lilly expects to file with the FDA by end of March 2027. 

(2) Lilly's amylin + tirzepatide combo EloraTZP: 23.3% at 48 weeks heading to Phase 3, with a real tolerability question — plus the wider amylin stacking moment. 

(3) Boehringer/Zealand's survodutide Phase 3 SYNCHRONIZE-2: 13.1% at 76 weeks, published in NEJM the same day. 

(4) Novo's oral strategy: up to $2.6B for ex-China rights to Hengrui's weekly oral GLP-1/GIP, real-world data on switching to the Wegovy pill, and Wegovy liver-fat normalization. 

(5) The FDA's warning letter to Empower Pharmacy over mass-produced compounded GLP-1s — its fourth. Plus a market check: LLY dipped on great news, NVO down ~24% YTD.

For research and informational purposes only — not medical advice.

**Sources:**
- Cardiac Wire — TRIUMPH-1 full Phase 3: https://cardiacwire.com/a-new-king-of-the-glp-1s-could-be-crowned/
- USA Today — TRIUMPH-2 / Lilly FDA filing plans: https://www.usatoday.com/story/money/personal-finance/healthcare/2026/09/30/retatrutide-glp-1-eli-lilly-weight-loss/92019663007/
- BioSpace — EloraTZP Phase 2b: https://www.biospace.com/drug-development/superior-weight-loss-blood-sugar-control-propel-lillys-amylin-gip-glp-1-combo-into-phase-3
- Zealand Pharma — SYNCHRONIZE-2: https://mfn.se/one/a/zealand-pharma/zealand-pharma-announces-boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-diabetes-a9e0d011
- Business News Today — Novo–Hengrui $2.6B deal: https://business-news-today.com/hengrui-lands-2-6bn-novo-nordisk-deal-for-experimental-weekly-oral-obesity-drug/
- Reuters — OCTANE real-world switching study: https://www.reuters.com/legal/litigation/patients-switching-to-novo-nordisks-wegovy-pill-shots-lose-more-weight-real-2026-09-30/
- Becker's Hospital Review — FDA warning letter to Empower Pharmacy: https://www.beckershospitalreview.com/pharmacy/fda-flags-sterility-concerns-at-major-glp-1-compounder/

]]> Buzzsprout-19897615 Fri, 02 Oct 2026 05:00:00 -0400 558 1 2 full false Peptalk Pilot: Deep Dive — NAD+ Peptalk Pilot: Deep Dive — NAD+ Welcome to Peptalk! In our pilot episode, Jake and Cynthia go deep on NAD+ (nicotinamide adenine dinucleotide) — one of the most talked-about molecules in the peptide world right now, even though it's not technically a peptide at all.

We open with a fast GLP-1 pulse: retatrutide's showstopping EASD 2026 data (28.3% weight loss at 80 weeks), a warning about gray-market vials, Lilly's oral orforglipron vs. oral semaglutide, and Novo's deal with Nanexa on long-acting delivery.

Then the deep dive: what NAD+ actually does in the body (mitochondrial energy, sirtuin activation, DNA repair), the formats it's sold in (IV drips, injections, oral NR/NMN precursors, nasal spray), and what a 2026 systematic review really found — precursors reliably raise blood NAD+ metabolites, but functional outcomes are mixed, and there are zero clinical trials of IV NAD+ for wellness. Plus the cell-membrane problem, the GLP-1 stacking rationale, safety data, and an honest bottom line.

For research and informational purposes only — not medical advice.

**Sources:**
- StackTrax NAD+ guide: https://stacktrax.com/guides/nad-plus
- Frontiers in Aging — IV NAD+ and precursors in wellness: https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2026.1887175/full
- NPR/WAMC — "Marketers say NAD+ pills and infusions can boost longevity. What's the evidence?": https://www.wamc.org/2026-05-11/marketers-say-nad-pills-and-infusions-can-boost-longevity-whats-the-evidence
- Key Wellness — NAD+ therapy research summary: https://www.keytwellness.com/post/nad-therapy-cellular-energy-and-what-the-research-shows
- Abby Langer — "The NAD+ Anti-Aging Hype, Explained": https://bitemebyabbylanger.substack.com/p/can-nad-really-slow-aging
- Medical Daily — EASD 2026 retatrutide data preview: https://www.medicaldaily.com/easd-2026-retatrutide-mounjaro-wegovy-pill-data-preview-479203
- Morningstar/PR Newswire — Lilly's orforglipron vs. oral semaglutide: https://www.morningstar.com/news/pr-newswire/20260929de57460/lillys-foundayo-orforglipron-172-mg-showed-greater-weight-loss-and-a1c-reduction-than-oral-semaglutide-25-mg-among-adults-with-type-2-diabetes-in-a-new-indirect-treatment-comparison

]]> Welcome to Peptalk! In our pilot episode, Jake and Cynthia go deep on NAD+ (nicotinamide adenine dinucleotide) — one of the most talked-about molecules in the peptide world right now, even though it's not technically a peptide at all.

We open with a fast GLP-1 pulse: retatrutide's showstopping EASD 2026 data (28.3% weight loss at 80 weeks), a warning about gray-market vials, Lilly's oral orforglipron vs. oral semaglutide, and Novo's deal with Nanexa on long-acting delivery.

Then the deep dive: what NAD+ actually does in the body (mitochondrial energy, sirtuin activation, DNA repair), the formats it's sold in (IV drips, injections, oral NR/NMN precursors, nasal spray), and what a 2026 systematic review really found — precursors reliably raise blood NAD+ metabolites, but functional outcomes are mixed, and there are zero clinical trials of IV NAD+ for wellness. Plus the cell-membrane problem, the GLP-1 stacking rationale, safety data, and an honest bottom line.

For research and informational purposes only — not medical advice.

**Sources:**
- StackTrax NAD+ guide: https://stacktrax.com/guides/nad-plus
- Frontiers in Aging — IV NAD+ and precursors in wellness: https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2026.1887175/full
- NPR/WAMC — "Marketers say NAD+ pills and infusions can boost longevity. What's the evidence?": https://www.wamc.org/2026-05-11/marketers-say-nad-pills-and-infusions-can-boost-longevity-whats-the-evidence
- Key Wellness — NAD+ therapy research summary: https://www.keytwellness.com/post/nad-therapy-cellular-energy-and-what-the-research-shows
- Abby Langer — "The NAD+ Anti-Aging Hype, Explained": https://bitemebyabbylanger.substack.com/p/can-nad-really-slow-aging
- Medical Daily — EASD 2026 retatrutide data preview: https://www.medicaldaily.com/easd-2026-retatrutide-mounjaro-wegovy-pill-data-preview-479203
- Morningstar/PR Newswire — Lilly's orforglipron vs. oral semaglutide: https://www.morningstar.com/news/pr-newswire/20260929de57460/lillys-foundayo-orforglipron-172-mg-showed-greater-weight-loss-and-a1c-reduction-than-oral-semaglutide-25-mg-among-adults-with-type-2-diabetes-in-a-new-indirect-treatment-comparison

]]> Brian Buzzsprout-19885513 Tue, 29 Sep 2026 22:00:00 -0400 700 1 1 full false